Neimeth International Pharmaceuticals

What Neimeth International Pharmaceuticals does

Neimeth International Pharmaceuticals Plc is a Nigerian pharmaceutical manufacturer headquartered in Lagos, operating across three product lines: Ethical Products (prescription antimalarials, antihypertensives, antibiotics, antifungals, and specialty items such as Ciklavit for sickle cell management), Healthcare Products (consumer items including the NCP antiseptic franchise, Obron-6 prenatal vitamins, and Homtamin G stress supplement), and Veterinary Products (animal health antibiotics and dewormers). The company was established in 1992 when Pfizer divested its Nigerian operations and has operated independently since recapitalization in 2005; it is listed on the Nigerian Exchange under the ticker NEIMETH.

The company's technology base is conventional pharmaceutical manufacturing — GMP-compliant production of tablets, capsules, ointments, creams, oral liquids, powders, and consumer liquids at a 20-acre Lagos campus with NAFDAC and PCN certification, ISO 9001 and ISO 14001 dual certification, and an in-house water treatment facility. Notable proprietary products include Ciklavit (first indigenous sickle cell supplement derived from Cajanus cajan), Pyrantrin Choco (first chocolate-flavored dewormer in Nigeria), and the multi-format NCP antiseptic line. A WHO-standard pharmaceutical complex is under construction in Amawbia, Anambra State.

Neimeth earns revenue primarily through sale of prescription and consumer pharmaceuticals and veterinary products via a territorial field sales structure covering Nigeria and ECOWAS markets, distributed through a network of 30+ retail pharmacies and community health programs. Secondary revenue comes from contract manufacturing and tolling using idle plant capacity. FY2025 revenue reached N7.37 billion (64% YoY growth), with a pre-tax profit of N1.49 billion representing a turnaround from a N854.43 million loss in 2024. The company is funding further expansion through a planned N20 billion capital raise.

Name

Neimeth International Pharmaceuticals

Legal name

Neimeth International Pharmaceuticals Plc

Website

https://neimethplc.com.ng

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Short description

Neimeth International Pharmaceuticals Plc is a Nigerian pharmaceutical manufacturer producing prescription drugs, veterinary medicines, and consumer healthcare products for the Nigerian and ECOWAS markets. The company operates GMP-certified manufacturing facilities in Lagos with a diversified portfolio addressing malaria, hypertension, deworming, sickle cell, and animal health.

Ownership category

akta.pro rank

Headquarters

HQ city

Lagos

HQ country

Nigeria

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical and Veterinary Product Sales: Sale of ethical (prescription) pharmaceuticals, healthcare/consumer products, and veterinary products across Nigeria and ECOWAS markets. Revenue grew 64% YoY to N7.37 billion in 2025, driven by pharmaceutical segment sales of N7.18 billion.
2. Contract Manufacturing / Tolling: Idle or excess plant capacity is deployed to contract manufacturing and tolling for other companies and institutions, leveraging capabilities in tableting, encapsulation, ointments, liquids, labelling, packaging, blistering, and powder filling.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Neimeth manufactures and distributes ethical (prescription) pharmaceuticals, healthcare consumer products, and veterinary pharmaceuticals across Nigeria and ECOWAS markets. Its portfolio addresses malaria, hypertension, deworming, sickle cell disease, fungal and bacterial infections, maternal nutrition, and animal health, produced at a GMP-compliant facility in Lagos. The company also offers contract manufacturing and tolling services using idle plant capacity.

Product overview

Neimeth International Pharmaceuticals Plc is a Nigerian pharmaceutical manufacturer offering a diversified portfolio of human ethical drugs, veterinary products, and healthcare consumer items. The company operates three product lines: Ethical Products (prescription pharmaceuticals including antimalarials, antihypertensives, antibiotics, antifungals, and specialty products like Ciklavit for sickle cell management), Veterinary Products (animal health antibiotics and dewormers including Neomycin formulations and Neimeth Piperazine), and Healthcare Products (consumer items like NCP antiseptic/disinfectant line, Obron-6 prenatal vitamins, and Homtamin G stress supplements). The product portfolio addresses therapeutic areas including malaria, hypertension, cardiovascular health, infectious diseases, and nutrition, with manufacturing facilities in Lagos operating under GMP and NAFDAC certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Ciklavit

Quantifiable outcome

• Revenue grew 64% year-on-year to N7.37 billion in 2025
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• National Association of Nigerian Nurses and Midwives (NANNM)coreStrategic or Co-development PartnerStrategic alliance forged in 2015 to promote maternal and child health in Nigeria. The association endorsed Obron-6, a multivitamin and mineral supplement for pregnant and lactating mothers, based on efficacy reports. The partnership involves joint advocacy, awareness campaigns, and product promotion.
• Young Pharmacists Group (YPG), Imo State ChapterminorStrategic or Co-development PartnerPartnership for free mass deworming exercise (Operation Deworm Dem!) carried out in September 2022 at Relief Market, Owerri, Imo State in commemoration of World Pharmacists Day. Neimeth provided Unaben (Albendazole) products while YPG members conducted the deworming exercise and health education.
• SeplatminorOthersCSR partnership where Neimeth donated 5000 units of NCP 25ml hand antiseptic to Seplat during the Ebola Virus Disease outbreak in 2014 for distribution to Seplat's host communities. Seplat had been a valued buyer of Neimeth products over the years.
• Nigeria Heart Foundation, Hypertension Society of Nigeria, Pharmaceutical Society of Nigeria, OMRONcoreStrategic or Co-development PartnerCoalition partners for the FITGAH (Fight The Good Fight Against Hypertension) program launched in May 2013. Partners collaborate on mass screening for hypertension, provision of drugs at subsidized rates, and lifestyle modification education programs across Nigeria's geo-political zones.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• May & Baker Nigeria Plc: Nigerian pharmaceutical manufacturer with a comparable portfolio of ethical drugs, consumer health, and veterinary products. Highly comparable in size, product mix, and West African market focus — and a known former employer of Neimeth's current MD/CEO.
• Fidson Healthcare Plc: Leading Nigerian pharmaceutical manufacturer listed on the NGX, producing branded generics and consumer health products. Closely comparable in scale, listing status, and product portfolio mix to Neimeth.
• Emzor Pharmaceutical Industries Limited: Major Nigerian pharmaceutical manufacturer with broad portfolio of ethical drugs, antimalarials, and consumer health products. Direct competitor in the same Lagos/Nigeria market with overlapping therapeutic categories.
• Chi Pharmaceuticals Limited: Nigerian pharmaceutical manufacturer focused on antimalarials, antibiotics, and consumer health products. Comparable size and West African market focus with overlapping ethical product categories.
• Afrab Chem Limited: Nigerian pharmaceutical and consumer goods manufacturer producing ethical drugs, OTC products, and household disinfectants. Comparable scale and overlapping antiseptic/consumer health lines (relevant for NCP).

Broad incumbents

• GlaxoSmithKline Consumer Nigeria Plc: Multinational pharmaceutical and consumer health company operating in Nigeria. Broader portfolio with established brands; competes with Neimeth in OTC consumer health and ethical pharmaceutical segments.
• Sanofi Nigeria: Multinational pharmaceutical company with Nigeria operations across prescription drugs, vaccines, and consumer health. Broad incumbent competing with Neimeth's ethical and consumer health lines; cited in the data as one of the multinationals exiting Nigeria.
• AstraZeneca Nigeria: Multinational pharma with Nigeria presence, focused on cardiovascular, respiratory, and oncology therapies. Competes with Neimeth's antihypertensive and ethical product lines as a broader incumbent player.
• Pfizer Products Nigeria: Multinational pharmaceutical company and Neimeth's corporate ancestor (Neimeth was formed from Pfizer's Nigerian divestment in 1992). Directly relevant for inherited product heritage, talent, and competitive overlap.

Regional players

• Aspen Pharmacare Holdings Limited: Largest African pharmaceutical manufacturer based in South Africa with broad generics, OTC, and consumer health portfolio. Regional peer for African pharma manufacturing scale and emerging-market distribution strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neimethplc2

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neimeth International Pharmaceuticals